Key Capital Management’s Royalty Pharma RPRX Stock Holding History

Key Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.97K	Buy	+53	New	+$2.76K	﹤0.01%	519

Other funds holding RPRX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking Tokyo, Japan $45.7B AUM 34.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Key Capital Management's RPRX Position: Q2 2026 in Review

Key Capital Management opened a new position in Royalty Pharma (RPRX) in Q2 2026: 53 shares worth $2.97K. The stake represents ﹤0.01% of the portfolio and ranks #519 among its holdings.

257 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Key Capital Management held 53 shares of Royalty Pharma worth $2.97K as of Q2 2026.
Royalty Pharma was a new Key Capital Management position in Q2 2026.
Royalty Pharma made up ﹤0.01% of Key Capital Management's portfolio in Q2 2026, its #519 holding.
257 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Key Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.